NCT00396721View on ClinicalTrials.gov

Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

October 31, 2009

Study Completion Date

February 28, 2010

Conditions
Glomerulonephritis, IGANephropathy, IGAIGA Nephropathy
Interventions
DRUG

ACE inhibitor + statin

sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d

DRUG

Sirolimus (study drug)+ACE inhibitor + statin

enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d

Trial Locations (1)

08907

Nephrology Department. Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Josep m Cruzado

OTHER

NCT00396721 - Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy | Biotech Hunter | Biotech Hunter